Predicting Intention to Receive COVID-19 Vaccination in People Living with HIV using an Integrated Behavior Model

Author:

Wicaksana Bramantya1,Yunihastuti Evy2ORCID,Shatri Hamzah1,Pelupessy Dicky C.3,Koesnoe Sukamto2,Djauzi Samsuridjal4,Mahdi Haridana Indah Setiawati4,Waluyo Dyah Agustina5,Djoerban Zubairi5,Siddiq Tommy Hariman6

Affiliation:

1. Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia—Cipto Mangunkusumo Hospital, Jakarta 10430, Indonesia

2. Allergy and Clinical Immunology Division, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Cipto Mangunkusumo Hospital, Jakarta 10430, Indonesia

3. Faculty of Psychology, Universitas Indonesia, Depok 16424, Indonesia

4. Department of Non-Oncology Internal Medicine, Dharmais National Cancer Hospital, Jakarta 11420, Indonesia

5. Kramat 128 Hospital, Jakarta 10430, Indonesia

6. Faculty of Psychology and Education, Universitas Al Azhar Indonesia, Jakarta 12110, Indonesia

Abstract

People living with HIV (PLHIV) are considered a high-risk population for developing a severe form of COVID-19. Vaccination is still one of the most important modalities in combating the disease due to the lack of an effective treatment. This multicenter study was performed from September to December 2021 with the aim to analyze the intention of PLHIV to receive the COVID-19 vaccination based on an integrated behavior model (IBM) in Indonesia. Of a total of 470 participants, 75.6% of patients were intent to be vaccinated. The model that was designed in this study explains 43.4% of the variance in intention to be vaccinated against COVID-19 in PLHIV (adjusted R2 = 0.434). Furthermore, the determinants used included instrumental attitude (β = 0.127, p < 0.05), subjective norm (β = 0.497, p < 0.01), and perceived behavioral control (β = 0.116, p < 0.01). This study concluded that an IBM could predict the intention of PLHIV to receive COVID-19 vaccination.

Funder

PUTI

Publisher

MDPI AG

Subject

Pharmacology (medical),Infectious Diseases,Drug Discovery,Pharmacology,Immunology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3